Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, April 2003, p. 1430-1432, Vol. 47, No. 4
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.4.1430-1432.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
D. A. Spratt,1 A. Villedieu,1 N. Hunt,2 M. Wilson,1 and P. Mullany1*
Department of Microbiology,1 Department of Orthodontics, Eastman Dental Institute, University College London, London, United Kingdom2
Received 7 October 2002/ Returned for modification 27 November 2002/ Accepted 23 January 2003
| ABSTRACT |
|---|
|
|
|---|
| TEXT |
|---|
|
|
|---|
Dental plaque and saliva samples were collected from 20 healthy adults who had not received antibiotics during the previous 3 months.
Bacteria were harvested by centrifugation (3,500 x g, 10 min, 4°C) from the saliva and plaque specimens. The resulting bacterial pellet was washed gently in sterile saline. Two aliquots of the cells were prepared, and DNA was extracted from one of these aliquots by using the Puregene gram-positive DNA isolation protocol and from the other by using the Puregene gram-negative DNA isolation protocol (Gentra Systems) according to the manufacturer's instructions. The extracted DNA was subsequently pooled. To prepare the DNA for library construction, 0.2 ml of DNA (at a concentration of 250 ng/ml) was sonicated for 5 s on ice at 80% power by using an ultrasonic homogenizer (IKA-WERKE). The ends of the DNA were repaired by treating them with 2 U of mung bean nuclease (Promega)/mg in a final volume of 100 µl at 37°C for 1 h to produce blunt ends. The resulting DNA fragments were separated by agarose gel electrophoresis, and fragments between 800 and 3,000 bp were cut from the gel and purified by using the Qiagen agarose purification kit. To generate 3'-A overhangs prior to cloning into a TOPO-XL vector, the DNA fragments were incubated at 75°C for 1 h with 1 U of Taq DNA polymerase (Bioline)/mg in a final volume of 100 µl in the presence of 2 mM dATP in 1x Taq buffer. Prior to ligation into the vector, the DNA was treated by using the Qiagen PCR purification kit. Ligation of DNA into TOPO-XL and subsequent transformation into E. coli TOP10 cells were performed according to the manufacturer's protocol. Plasmid DNA was isolated from E. coli by using the Qiagen Miniprep kit.
The library was screened on Luria-Bertani agar plates containing tetracycline at a concentration of 5 µg/ml. Plasmid DNA from antibiotic-resistant clones was used to retransform E. coli to confirm that antibiotic resistance was encoded on the insert DNA.
To detect the tetracycline resistance genes encoding ribosomal protection proteins [tet(M), tet(O), tetB(P), tet(Q), tet(S), tet(T)], PCRs with primers and cycling conditions previously reported (1) were used. tet(W) tet(37)-specific primers (Tet37F, 5'-AGGGATATTGGTTGGAGA-3'; Tet37R, 5'-ATCAGTCTCATATTTCGACA-3') were used in standard PCRs.
All PCR products were sequenced with forward primer XLF-2 (5'-CGC CAG TGT GAT GGA TAT-3') and reverse primer XL-2R (5'-TAG AAT ACT CAA GCT ATG C-3'). The sequencing reactions were performed by using the ABI PRISM BigDye Terminator cycle sequencing protocol on either an Applied Biosystems model 310 genetic analyzer or a model 373 DNA sequencer according to the manufacturer's instructions.
DNA sequences were analyzed with the DNAMAN version 5.2.2 program (Lynnon Biosoft). Similarity analysis was carried out with the Advance Blast program of GenBank (National Center for Biotechnology Information, National Institutes of Health, Washington, D.C.), and alignments were performed by using the CLUSTAL W program service at the European Bioinformatics Institute (http://www.ebi.ac.uk/).
The enzymatic activity of tet(37) was determined as previously described (3).
A total of 450 transformants were obtained from the genomic library. Of these, 18 (4%) were tetracycline resistant. These were screened by PCR for the presence of the previously characterized tetracycline resistance genes, and tet(M) and tet(O) were detected in two clones and tet(Q) was detected in one.
Some of the other clones were not homologous to sequences in the databases. However, one contained a novel tetracycline resistance gene, designated tet(37), which conferred an MIC for E. coli of 30 µg/ml aerobically but less than 1 µg/ml anaerobically. MICs for E. coli carrying only TOPO-XL were 1 µg/ml aerobically. The complete DNA sequence of the 390-bp tet(37) gene was obtained (GenBank accession number AF540889).
A BLAST search of the deduced amino acid sequence encoded by this gene showed that it is homologous to a number of proteins related to flavoproteins, oxidoreductases, and NAD(P)-requiring enzymes. The closest relative to Tet 37 in the database is from Fusobacterium nucleatum subsp. nucleatum strain ATCC 255 (GenBank accession number AE010563.1), with 44% identity. A multiple alignment of Tet 37 with other oxidoreductases is presented in Fig. 1 and shows conserved motifs between Tet 37 and these oxidoreductases.
|
|
That tetracycline was being inactivated was confirmed by a biological assay in which broth containing tetracycline was incubated with E. coli containing tet(37) or a control E. coli isolate containing tet(M) (a ribosome protection resistance gene) and then incorporated into fresh broth after filtration. Tetracycline-sensitive bacteria could grow in the broth that had previously been incubated with the organisms containing tet(37) but not in the broth that had been grown with the control organism.
The properties of tet(37) are similar to those of tet(X), originally isolated from Bacteroides (2). However there is no homology between the deduced amino acid sequence of Tet 37 and that of Tet X.
In conclusion, we have shown that antibiotic resistance genes can be cloned and expressed from DNA isolated from the whole array (i.e., cultivable and noncultivable) of oral microflora. It should be possible to use this technique to isolate all of the antibiotic resistance genes from a particular ecological niche regardless of whether or not the original host bacteria can be cultivated in the laboratory.
| ACKNOWLEDGMENTS |
|---|
We thank Rustam Aminov for supplying the strains carrying characterized tetracycline-resistant genes and A. Salyers for providing the E. coli strain carrying the tet(X) gene used as the control in this study.
| FOOTNOTES |
|---|
Present address: GlaxoSmithKline Consumer Healthcare, Surrey, United Kingdom. ![]()
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |